Jerry Karabelas

Argeris N. (“Jerry”) Karabelas, PhD

Dr. Karabelas is a Partner at Care Capital, a life-sciences venture capital firm based in Princeton, NJ. Before joining Care Capital, Jerry was Head of Healthcare and CEO of worldwide Pharmaceuticals for Novartis AG from 1998 until July 2000.

He had full responsibility for Novartis Pharma, Ciba Vision and Generics representing US $12 billion in annual sales. Included in these responsibilities was strategic and operational leadership of R&D with a budget in excess of US $2 billion.

Prior to joining Novartis, Jerry was Executive Vice President of SmithKline Beecham responsible for US operations, European operations, Regulatory, and Strategic Marketing. He has been responsible for numerous pharmaceutical product approvals and new product launches, including the launch of 3 US $1 billion products. Jerry was the Founder and Chairman of the Novartis Bio Venture Fund from July 2000 until December 2001.

In this role, he invested approximately $40 million in 14 portfolio companies. Jerry holds a Ph.D. in pharmacokinetics from the Massachusetts College of Pharmacy. He is a member of the Scientific Advisory Council of the Massachusetts General Hospital, the Visiting Committee for Health Sciences and Technology at MIT, and a Trustee of Fox Chase Cancer Center and the Philadelphia University of the Sciences. He is also a Director of Human Genome Sciences, SkyePharma Plc, Nitromed, Anadys and Renovo, and the acting chairman of Vanda Pharmaceuticals.